NIH R01 · 2025
Elucidate the landscape of druggable targets for eliminating cancer persister cells
PROJECT SUMMARY Residual disease, caused by incomplete killing of cancer cell populations, is a critical limitation of targeted therapy, and almost inevitability leads to tumor recurrence. A growing body of evidence suggests a significant contribution of persister cells to residual disease. Persister cells are small subpopulations of the original tumor that survive presumed lethal doses of targeted therapy via non-genetic mechanisms of drug tolerance. Eliminating persister populations before they have a chance to evolve genetic resistance mutations will improve the durability of targeted therapies. However, signals that promote and targets that eliminate persistence are poorly…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.